Krystal Biotech, Inc.
KRYS
$180.30
-$3.62-1.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 89.16M | 52.37M | 105.94M | 57.16M | 10.93M |
| Total Depreciation and Amortization | 3.21M | 3.88M | 4.32M | 4.24M | 4.81M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.50M | 41.91M | -64.50M | -67.14M | -66.03M |
| Change in Net Operating Assets | -14.46M | -34.82M | -62.50M | -41.03M | -38.52M |
| Cash from Operations | 123.42M | 63.35M | -16.74M | -46.76M | -88.80M |
| Capital Expenditure | -4.24M | -5.28M | -6.02M | -7.68M | -11.80M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 100.00M | 100.00M | 100.00M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -159.20M | -84.54M | -44.28M | -39.23M | -5.56M |
| Cash from Investing | -163.44M | -89.82M | 49.70M | 53.10M | 82.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 32.40M | 32.59M | 42.61M | 217.25M | 203.50M |
| Repurchase of Common Stock | -5.39M | -5.39M | -5.39M | -5.39M | -749.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 27.01M | 27.21M | 37.23M | 211.86M | 202.75M |
| Foreign Exchange rate Adjustments | -458.00K | -4.00K | -278.00K | 67.00K | -156.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.46M | 725.00K | 69.91M | 218.26M | 196.43M |
